Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)
China
· Delayed Price · Currency is CNY 14.58
+0.29 (2.03%)
At close: Mar 10, 2026
SHE:002365 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 791.78 | 833.34 | 959.37 | 1,426 | 1,546 | 1,166 | Upgrade
|
| Other Revenue | 5.47 | 5.47 | 13.52 | 36.57 | 19.54 | 6.87 | Upgrade
|
| Revenue | 797.25 | 838.81 | 972.89 | 1,462 | 1,565 | 1,173 | Upgrade
|
| Revenue Growth (YoY) | 1.07% | -13.78% | -33.48% | -6.58% | 33.47% | -14.42% | Upgrade
|
| Cost of Revenue | 679.67 | 672.79 | 722.37 | 991.13 | 1,212 | 820.06 | Upgrade
|
| Gross Profit | 117.57 | 166.02 | 250.52 | 471.32 | 353.73 | 352.8 | Upgrade
|
| Selling, General & Admin | 75.78 | 80.61 | 176.42 | 249.77 | 154.58 | 166.85 | Upgrade
|
| Research & Development | 32.68 | 36.97 | 41.5 | 40.45 | 53.04 | 46.66 | Upgrade
|
| Other Operating Expenses | 14.81 | 9.16 | 10.09 | 13.66 | 11.58 | 10.09 | Upgrade
|
| Operating Expenses | 122 | 126.05 | 226.39 | 301.41 | 228.94 | 225.14 | Upgrade
|
| Operating Income | -4.42 | 39.97 | 24.12 | 169.91 | 124.79 | 127.66 | Upgrade
|
| Interest Expense | -0.92 | -0.59 | -0.37 | -0.66 | -2.44 | -1.2 | Upgrade
|
| Interest & Investment Income | 36.98 | 40.78 | 27.39 | 12.62 | 24.2 | 25.99 | Upgrade
|
| Currency Exchange Gain (Loss) | 9.17 | 9.17 | 5.64 | 21.55 | -4.09 | -8.54 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.18 | -1.02 | -0.43 | -0.64 | -0.7 | -0.51 | Upgrade
|
| EBT Excluding Unusual Items | 35.62 | 88.32 | 56.35 | 202.77 | 141.76 | 143.39 | Upgrade
|
| Impairment of Goodwill | -0.52 | -0.52 | -8.25 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.02 | 4.43 | -34.55 | -30.34 | -0.28 | -1.19 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.97 | 0.19 | 45.02 | -0.38 | 0.25 | -0.01 | Upgrade
|
| Asset Writedown | -16.02 | -15.36 | -42.06 | -3.65 | -3.02 | -15.45 | Upgrade
|
| Legal Settlements | -10.02 | -10.02 | -23.3 | -22.73 | -13.61 | -4.94 | Upgrade
|
| Other Unusual Items | 6.2 | 3.82 | 12.84 | 7.4 | 4.75 | 8.78 | Upgrade
|
| Pretax Income | 20.26 | 70.86 | 6.05 | 153.06 | 129.85 | 130.58 | Upgrade
|
| Income Tax Expense | 3.01 | 11.15 | 34.47 | 20.34 | 10.81 | 11.92 | Upgrade
|
| Earnings From Continuing Operations | 17.25 | 59.71 | -28.41 | 132.72 | 119.05 | 118.66 | Upgrade
|
| Minority Interest in Earnings | 8.16 | 2.06 | 16.1 | 7.63 | -7.63 | -13.1 | Upgrade
|
| Net Income | 25.41 | 61.77 | -12.31 | 140.35 | 111.42 | 105.56 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | 0.19 | 3.63 | - | Upgrade
|
| Net Income to Common | 25.41 | 61.77 | -12.31 | 140.16 | 107.78 | 105.56 | Upgrade
|
| Net Income Growth | 715.62% | - | - | 25.97% | 5.55% | 17.38% | Upgrade
|
| Shares Outstanding (Basic) | 290 | 293 | 295 | 294 | 287 | 288 | Upgrade
|
| Shares Outstanding (Diluted) | 291 | 295 | 295 | 294 | 287 | 289 | Upgrade
|
| Shares Change (YoY) | -0.95% | - | 0.13% | 2.66% | -0.63% | 0.06% | Upgrade
|
| EPS (Basic) | 0.09 | 0.21 | -0.04 | 0.48 | 0.38 | 0.37 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.21 | -0.04 | 0.48 | 0.38 | 0.37 | Upgrade
|
| EPS Growth | 724.77% | - | - | 26.66% | 2.75% | 17.69% | Upgrade
|
| Free Cash Flow | 38.75 | -12.33 | 100.46 | 238.21 | 38.76 | 102.25 | Upgrade
|
| Free Cash Flow Per Share | 0.13 | -0.04 | 0.34 | 0.81 | 0.14 | 0.35 | Upgrade
|
| Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | - | 0.100 | Upgrade
|
| Dividend Growth | - | - | - | - | - | -33.33% | Upgrade
|
| Gross Margin | 14.75% | 19.79% | 25.75% | 32.23% | 22.60% | 30.08% | Upgrade
|
| Operating Margin | -0.56% | 4.76% | 2.48% | 11.62% | 7.97% | 10.88% | Upgrade
|
| Profit Margin | 3.19% | 7.36% | -1.27% | 9.58% | 6.88% | 9.00% | Upgrade
|
| Free Cash Flow Margin | 4.86% | -1.47% | 10.32% | 16.29% | 2.48% | 8.72% | Upgrade
|
| EBITDA | 91.37 | 152.65 | 159.3 | 293.53 | 240.75 | 240.72 | Upgrade
|
| EBITDA Margin | 11.46% | 18.20% | 16.37% | 20.07% | 15.38% | 20.52% | Upgrade
|
| D&A For EBITDA | 95.79 | 112.68 | 135.18 | 123.62 | 115.96 | 113.07 | Upgrade
|
| EBIT | -4.42 | 39.97 | 24.12 | 169.91 | 124.79 | 127.66 | Upgrade
|
| EBIT Margin | -0.56% | 4.76% | 2.48% | 11.62% | 7.97% | 10.88% | Upgrade
|
| Effective Tax Rate | 14.84% | 15.74% | 569.54% | 13.29% | 8.32% | 9.13% | Upgrade
|
| Revenue as Reported | 797.25 | 838.81 | 972.89 | 1,462 | 1,565 | 1,173 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.